$BPMC BLUEPRINT MEDICINES SWINGS 30% TO UPSIDE THIS WEEK

ALTHOUGH THE STOCK HAS JUMPED THIS WEEK, IT IS NOT TO LATE TO GET IN, BUYING PRESSURE IS IMMENSE AND THE STOCK HAS A EASY 50% UPSIDE POTENTIAL LEFT IN THE TANK, ON THE BACK OF GROWING EXPECTATION THE COMPANY WILL HAVE ITS FIRST APPROVED DRUG FOR SALE AND AT LAST GENERATE PROFITS .

AVERAGE ANALYSTS PRICE TARGET $118
AVERAGE ANALYSTS RECOMMENDATION BUY


COMPANY PROFILE
Blueprint Medicines Corp. is a precision therapy company, which focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy in October 2008 and is headquartered in Cambridge, MA.